AGC Biologics Announces New Facility

09.24.18

The process development & manufacturing site will contain single-use bioreactors at the 500 and 2000L scale

AGC Biologics announced that as part of its ongoing program to expand its production capacities globally, it will establish a new state of the art process development and manufacturing facility at its CDMO facility in Chiba, Japan.  

The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500 and 2000L scale and will be ideally suited for the production of monoclonal antibodies (MAbs), fusion proteins and other types of therapeutic proteins.

AGC Biologics currently provides mammalian protein process development and manufacturing services from its facilities in Bothell, WA; Berkeley, CA; and Copenhagen, Denmark, as well as microbial process development and manufacturing services from its facilities in Heidelberg, Germany; Copenhagen, Denmark; and Chiba, Japan.  The Company will leverage its extensive experience and expertise with mammalian production systems to rapidly establish these services at its site in Japan.

"This is a key investment for AGC Biologics that will expand our capabilities and reinforce our leadership position in the Japanese CDMO marketplace," said Gustavo Mahler, PhD, chief executive officer of AGC Biologics.  "Our new mammalian capabilities will represent a unique and convenient option for companies in Asia seeking mammalian production services nearby and for US and European companies seeking production in Asia."